Biodexa Pharmaceuticals (NASDAQ:BDRX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Biodexa Pharmaceuticals (NASDAQ:BDRX) from a sell rating to a hold rating in a research report sent to investors on Friday morning.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Biodexa Pharmaceuticals in a research note on Monday, December 29th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has an average rating of “Sell”.

Biodexa Pharmaceuticals Trading Down 0.9%

Shares of BDRX stock opened at $2.15 on Friday. Biodexa Pharmaceuticals has a 1-year low of $2.03 and a 1-year high of $92.00. The stock’s fifty day simple moving average is $3.69 and its 200-day simple moving average is $5.80.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease.